Feasibility study of transjugular tricuspid valve replacement for the treatment of tricuspid regurgitation
10.3760/cma.j.cn112148-20250127-00072
- VernacularTitle:经颈静脉介入三尖瓣置换治疗三尖瓣反流的可行性研究
- Author:
Fei CHEN
1
;
Zhengang ZHAO
;
Xin WEI
;
Yujia LIANG
;
Zhongkai ZHU
;
Yijun YAO
;
Xi LI
;
Qiao LI
;
Jiafu WEI
;
Wei MENG
;
Yong PENG
;
Yuan FENG
;
Mao CHEN
Author Information
1. 四川大学华西医院心脏内科，成都 610041
- Publication Type:Journal Article
- Keywords:
Tricuspid valve;
Tricuspid regurgitation;
Transcatheter tricuspid valve replacement;
Permanent pacemaker;
Bleeding
- From:
Chinese Journal of Cardiology
2025;53(4):363-372
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the feasibility of transjugular transcatheter tricuspid valve replacement (TTVR) using the LuX-Valve Plus system (Ningbo Jenscare Scientific, China) for the treatment of severe tricuspid regurgitation in real-world clinical settings.Methods:This prospective study enrolled 81 patients with severe ricuspid regurgitation (≥3+) who underwent TTVR with the LuX-Valve Plus system at the Department of Cardiology, West China Hospital of Sichuan University between May 2022 and March 2024. Among them, 44 patients were from a compassionate-use study, and 37 were from two premarket clinical trials. Baseline clinical data, preprocedural imaging, procedural outcomes, and postprocedural follow-up data were collected. The primary endpoint events included device success, procedural success, and 30 d composite adverse events.Results:The age of the cohort was (74.5±7.8) years, with 54 females (67%). Device success and procedural success rates were both 90% (73/81). Post-procedural tricuspid regurgitation improved, with a 6% (5/81) incidence of moderate-to-severe paravalvular leakage. The rate of permanent pacemaker implantation was 12% (10/81), of which 5% (4/81) had pre-existing indications for pacemaker implantation. Major bleeding events occurred in 10% (8/81) of patients, and the 30 d composite endpoint rate was 25% (20/81).Conclusion:TTVR using the LuX-Valve Plus system demonstrates promising feasibility for high-risk surgical patients with severe tricuspid regurgitation, effectively reducing or eliminating regurgitation with acceptable safety. However, challenges remain in reducing risks of major adverse events, including permanent pacemaker implantation and severe bleeding.
